The DOI matches its Crossref record.
Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms
Abstract
) and comorbid depression and/or anxiety symptoms. Participants received viloxazine ER (200-600 mg/d) for 14 weeks added to existing medications (including stimulant, antidepressant, or anxiolytic medications). Efficacy and safety measures (assessed via televisit, mobile phone app, and home monitoring devices) included clinician-and patient-reported scales evaluating ADHD, depression, and anxiety symptoms, treatment-emergent adverse events, blood pressure, pulse rate, weight, and suicidality assessment. The primary end point was change from baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) total score. <.0001). Safety outcomes were consistent with previous viloxazine ER studies; 24 participants (14.9%) had adverse events leading to study discontinuation. Viloxazine ER was well tolerated and associated with improvements in ADHD, depression, and anxiety symptoms in this real-world study of adults with ADHD and comorbid symptoms. ClinicalTrials.gov identifier: NCT06185985.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cited by
Sorted by citations
New and emerging therapeutics and molecular targets for attention-deficit hyperactivity disorder
Haavik, J. (2026) · Expert opinion on therapeutic targets · doi:10.1080/14728222.2026.2747529
Metadata
- Authors
- Adler, L. A., Lieberman, V. R., Brijbasi, L., Mattingly, G. W., Yarullina, I., Li, Y., Earnest, J., & Rubin, J.
- Affiliations
- New York University (US)
- Supernus Pharmaceuticals (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2026-05-27
- Volume
- 87
- Issue
- 2
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W7162571646
- Semantic Scholar
- 2e327e901e5e0baf970bfabeeaedbfc998c29de7
- Cited by
- 1
- References
- 0
- Citations by year
- 2026: 1
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- adult ADHD, comorbid depression, anxiety comorbidity, treatment-emergent adverse events, suicidality, home monitoring, mobile phone app, real-world evidence
- MeSH terms
- Adult, Anxiety, Attention Deficit Disorder with Hyperactivity, Delayed-Action Preparations, Depression, Female, Humans, Male, Middle Aged, Viloxazine, Treatment Outcome, Adrenergic Uptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
